Insight on AV-45 binding in white and grey matter from histogram analysis: A study on early Alzheimer's disease patients and healthy subjects

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 41, Issue 7, 2014, Pages 1408-1418

  Nemmi, Federico ^a,b   Saint Aubert, Laure ^a,b   Adel, Djilali ^a,b   Salabert, Anne Sophie ^a,b   Pariente, Jérémie ^a,b   Barbeau, Emmanuel J ^a,b   Payoux, Pierre ^a,b   Péran, Patrice ^a,b  

^a TOULOUSE UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE TOULOUSE   (France)

Author keywords

Alzheimer's disease; Amyloid; AV 45; Discrimination analysis; Intensity histogram

Indexed keywords

AMYLOID; FLORBETAPIR; RADIOLIGAND; UNCLASSIFIED DRUG; ANILINE DERIVATIVE; ETHYLENE GLYCOL DERIVATIVE; PROTEIN BINDING;

AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; CLUSTER ANALYSIS; CONTROLLED STUDY; FEMALE; GRAY MATTER; HISTOGRAM; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PROTEIN BINDING; WHITE MATTER; CASE CONTROL STUDY; DIAGNOSTIC USE; DISCRIMINANT ANALYSIS; METABOLISM; SCINTISCANNING;

AGED; ALZHEIMER DISEASE; AMYLOID; ANILINE COMPOUNDS; CASE-CONTROL STUDIES; CLUSTER ANALYSIS; DISCRIMINANT ANALYSIS; ETHYLENE GLYCOLS; FEMALE; GRAY MATTER; HUMANS; MALE; POSITRON-EMISSION TOMOGRAPHY; PROTEIN BINDING; WHITE MATTER;

EID: 84903707993     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-014-2728-4     Document Type: Article

References (37)

1. Choi SR et al. Preclinical properties of 18F-AV-45: a PET agent for Abeta plaques in the brain. J Nucl Med. 2009;50(11):1887-94.
2. Carpenter Jr AP et al. The use of the exploratory IND in the evaluation and development of 18F-PET radiopharmaceuticals for amyloid imaging in the brain: a review of one company's experience. Q J Nucl Med Mol Imaging. 2009;53(4):387-93.
3. Clark CM et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-beta plaques: a prospective cohort study. Lancet Neurol. 2012;11(8):669-78.
4. Clark CM et al. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA. 2011;305(3):275-83.
5. Lin KJ et al. Whole-body biodistribution and brain PETimaging with [18F]AV-45, a novel amyloid imaging agent-a pilot study. Nucl Med Biol. 2010;37(4):497-508.
6. Wong DF et al. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18). J Nucl Med. 2010;51(6):913-20.
7. Saint-Aubert L et al. Cortical florbetapir-PET amyloid load in prodromal Alzheimer 's disease patients. Eur J Nucl Med Mol Imaging. 2013;3(1):43.
8. Camus Vet al. Using PET with 18F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment. Eur J Nucl Med Mol Imaging. 2012;39(4):621-31.
9. Fleisher AS et al. Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. Arch Neurol. 2011;68(11):1404-11.
10. La Joie R et al. Region-specific hierarchy between atrophy, hypometabolism, and beta-amyloid (Abeta) load in Alzheimer's disease dementia. J Neurosci. 2012;32(46):16265-73.
11. Rodrigue KM et al. beta-Amyloid burden in healthy aging: regional distribution and cognitive consequences. Neurology. 2012;78(6):387-95.
12. Villemagne VL et al. Amyloid imaging with (18)F-florbetaben in Alzheimer disease and other dementias. J Nucl Med. 2011;52(8):1210-7.
13. Villemagne VL et al. Comparison of 11C-PiB and 18F-florbetaben for Abeta imaging in ageing and Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2012;39(6):983-9.
14. Fodero-Tavoletti MT et al. Characterization of PiB binding to white matter in Alzheimer disease and other dementias. J Nucl Med. 2009;50(2):198-204.
15. Dubois B et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007;6(8):734-46. (Pubitemid 47058377)
16. Wallon D et al. The French series of autosomal dominant early onset Alzheimer's disease cases: mutation spectrum and cerebrospinal fluid biomarkers. J Alzheimers Dis. 2012;30(4):847-56.
17. Fleiss JL, Nee JCM, Landis JR. Large sample variance of kappa in the case of different sets of raters. Psychol Bull. 1979;86(5):974-7.
18. Kyriazi S et al. Metastatic ovarian and primary peritoneal cancer: assessing chemotherapy response with diffusion-weighted MR imaging-value of histogram analysis of apparent diffusion coefficients. Radiology. 2011;261(1):182-92.
19. Pope WB et al. Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. Radiology. 2009;252(1):182-9.
20. Pope WB et al. Apparent diffusion coefficient histogram analysis stratifies progression-free survival in newly diagnosed bevacizumab-treated glioblastoma. AJNR Am J Neuroradiol. 2011;32(5):882-9.
21. Conover WJ, Iman RL. Rank transformations as a bridge between parametric and nonparametric statistics - rejoinder. Am Stat. 1981;35(3):132-3.
22. Barthel H et al. Cerebral amyloid-beta PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol. 2011;10(5):424-35.
23. Canu E et al. Mapping the structural brain changes in Alzheimer's disease: the independent contribution of two imaging modalities. J Alzheimers Dis. 2011;26 Suppl 3:263-74.
24. Firbank MJ et al. Diffusion tensor imaging in Alzheimer's disease and dementia with Lewy bodies. Psychiatry Res. 2011;194(2):176-83.
25. 18F- flutemetamol PET using machine learning: comparison with visual reads and structural MRI. Neuroimage. 2013;64:517-25.
26. Kim JH et al. Regional white matter hyperintensities in normal aging, single domain amnestic mild cognitive impairment, and mild Alzheimer 's disease. J Clin Neurosci. 2011;18(8):1101-6.
27. Makedonov I, Black SE, MacIntosh BJ. Cerebral small vessel disease in aging and Alzheimer's disease: a comparative study using MRI and SPECT. Eur J Neurol. 2013;20(2):243-50.
28. Chao LL et al. Associations between white matter hyperintensities and beta amyloid on integrity of projection, association, and limbic fiber tracts measured with diffusion tensor MRI. PLoS One. 2013;8(6):e65175.
29. Hong YT, et al. Amyloid imaging with carbon 11-labeled Pittsburgh compound B for traumatic brain injury. JAMA Neurol. 2014;71(1):23-31.
30. Gurol ME, et al. Cerebral amyloid angiopathy burden associated with leukoaraiosis: A positron emission tomography/magnetic resonance imaging study. Ann Neurol. 2013;73(4):529-536.
31. Casanova R, Hsu F-C, Espeland MA, Alzheimer's Disease Neuroimaging Initiative. Classification of structural MRI images in Alzheimer's disease from the perspective of ill-posed problems. PLoS One. 2012;7(10):e44877.
32. Jagust W et al. What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia? Neurology. 2007;69(9):871-7. (Pubitemid 47329586)
33. Westman E, Muehlboeck JS, Simmons A. Combining MRI and CSF measures for classification of Alzheimer's disease and prediction of mild cognitive impairment conversion. Neuroimage. 2012;62(1):229-38.
34. Wolz R et al. Multi-method analysis of MRI images in early diagnostics of Alzheimer's disease. PLoS One. 2011;6(10):e25446.
35. Jeon Tet al. Regional changes of cortical mean diffusivities with aging after correction of partial volume effects. Neuroimage. 2012;62(3):1705-16.
36. Stadlbauer A et al. Magnetic resonance fiber density mapping of agerelated white matter changes. Eur J Radiol. 2012;81(12):4005-12.
37. Watanabe H et al. Progression and prognosis inmultiple system atrophy: an analysis of 230 Japanese patients. Brain. 2002;125(Pt 5):1070-83. (Pubitemid 34464618)